Global and United State Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, Status and Forecast 2023-2027

Report ID: 1015063 | Published Date: Jan 2025 | No. of Page: 106 | Base Year: 2024 | Rating: 4.2 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Intravenous
        1.2.3 Oral
        1.2.4 Subcutaneous
        1.2.5 Others
    1.3 Market by Application
        1.3.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Perspective (2016-2027)
    2.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Growth Trends by Regions
        2.2.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Share by Regions (2016-2021)
        2.2.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Regions (2022-2027)
    2.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Industry Dynamic
        2.3.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Trends
        2.3.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers
        2.3.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Challenges
        2.3.4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Revenue
        3.1.1 Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Revenue (2016-2021)
        3.1.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Players (2016-2021)
    3.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue
    3.4 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Concentration Ratio
        3.4.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in 2020
    3.5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Key Players Head office and Area Served
    3.6 Key Players Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Solution and Service
    3.7 Date of Enter into Neuromyelitis Optica Spectrum Disorder (NMOSD) Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Breakdown Data by Type
    4.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Type (2016-2021)
    4.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Type (2022-2027)

5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Breakdown Data by Application
    5.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Application (2016-2021)
    5.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2016-2027)
    6.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
        6.2.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021)
        6.2.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027)
        6.2.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2027)
    6.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
        6.3.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021)
        6.3.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027)
        6.3.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2027)
    6.4 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
        6.4.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021)
        6.4.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2016-2027)
    7.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
        7.2.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021)
        7.2.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027)
        7.2.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2027)
    7.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
        7.3.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021)
        7.3.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027)
        7.3.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2027)
    7.4 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
        7.4.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021)
        7.4.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2016-2027)
    8.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
        8.2.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2027)
    8.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
        8.3.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2027)
    8.4 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region
        8.4.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2016-2027)
    9.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
        9.2.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021)
        9.2.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027)
        9.2.3 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2027)
    9.3 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
        9.3.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021)
        9.3.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027)
        9.3.3 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2027)
    9.4 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
        9.4.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021)
        9.4.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2016-2027)
    10.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
        10.2.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2027)
    10.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
        10.3.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2027)
    10.4 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
        10.4.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 F. Hoffmann-La Roche Ltd
        11.1.1 F. Hoffmann-La Roche Ltd Company Details
        11.1.2 F. Hoffmann-La Roche Ltd Business Overview
        11.1.3 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
        11.1.4 F. Hoffmann-La Roche Ltd Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
        11.1.5 F. Hoffmann-La Roche Ltd Recent Development
    11.2 Alexion Pharmaceuticals
        11.2.1 Alexion Pharmaceuticals Company Details
        11.2.2 Alexion Pharmaceuticals Business Overview
        11.2.3 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
        11.2.4 Alexion Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
        11.2.5 Alexion Pharmaceuticals Recent Development
    11.3 RemeGen
        11.3.1 RemeGen Company Details
        11.3.2 RemeGen Business Overview
        11.3.3 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
        11.3.4 RemeGen Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
        11.3.5 RemeGen Recent Development
    11.4 Nihon Pharmaceutical
        11.4.1 Nihon Pharmaceutical Company Details
        11.4.2 Nihon Pharmaceutical Business Overview
        11.4.3 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
        11.4.4 Nihon Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
        11.4.5 Nihon Pharmaceutical Recent Development
    11.5 Harbour BioMed
        11.5.1 Harbour BioMed Company Details
        11.5.2 Harbour BioMed Business Overview
        11.5.3 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
        11.5.4 Harbour BioMed Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
        11.5.5 Harbour BioMed Recent Development
    11.6 Lundbeck
        11.6.1 Lundbeck Company Details
        11.6.2 Lundbeck Business Overview
        11.6.3 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
        11.6.4 Lundbeck Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
        11.6.5 Lundbeck Recent Development
    11.7 Bionure
        11.7.1 Bionure Company Details
        11.7.2 Bionure Business Overview
        11.7.3 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
        11.7.4 Bionure Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
        11.7.5 Bionure Recent Development
    11.8 Opexa Therapeutics
        11.8.1 Opexa Therapeutics Company Details
        11.8.2 Opexa Therapeutics Business Overview
        11.8.3 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
        11.8.4 Opexa Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
        11.8.5 Opexa Therapeutics Recent Development
    11.9 TG Therapeutics
        11.9.1 TG Therapeutics Company Details
        11.9.2 TG Therapeutics Business Overview
        11.9.3 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
        11.9.4 TG Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
        11.9.5 TG Therapeutics Recent Development
    11.10 Bio-Thera Solutions
        11.10.1 Bio-Thera Solutions Company Details
        11.10.2 Bio-Thera Solutions Business Overview
        11.10.3 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
        11.10.4 Bio-Thera Solutions Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
        11.10.5 Bio-Thera Solutions Recent Development
    11.11 Boston Pharmaceuticals
        11.11.1 Boston Pharmaceuticals Company Details
        11.11.2 Boston Pharmaceuticals Business Overview
        11.11.3 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
        11.11.4 Boston Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
        11.11.5 Boston Pharmaceuticals Recent Development
    11.12 Cour Pharmaceutical
        11.12.1 Cour Pharmaceutical Company Details
        11.12.2 Cour Pharmaceutical Business Overview
        11.12.3 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
        11.12.4 Cour Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
        11.12.5 Cour Pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Intravenous
    Table 3. Key Players of Oral
    Table 4. Key Players of Subcutaneous
    Table 5. Key Players of Others
    Table 6. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 8. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Regions (2016-2021) & (US$ Million)
    Table 9. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Regions (2016-2021)
    Table 10. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 11. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Regions (2022-2027)
    Table 12. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Trends
    Table 13. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers
    Table 14. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Challenges
    Table 15. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints
    Table 16. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue by Players (2016-2021) & (US$ Million)
    Table 17. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Players (2016-2021)
    Table 18. Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) as of 2020)
    Table 19. Ranking of Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies by Revenue (US$ Million) in 2020
    Table 20. Global 5 Largest Players Market Share by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (CR5 and HHI) & (2016-2021)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Solution and Service
    Table 23. Date of Enter into Neuromyelitis Optica Spectrum Disorder (NMOSD) Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021) (US$ Million)
    Table 26. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Type (2016-2021)
    Table 27. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 28. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 29. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Share by Application (2016-2021) & (US$ Million)
    Table 30. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Application (2016-2021)
    Table 31. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 32. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 33. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021) (US$ Million)
    Table 34. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027) & (US$ Million)
    Table 35. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021) (US$ Million)
    Table 36. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027) & (US$ Million)
    Table 37. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021) & (US$ Million) 
    Table 38. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027) & (US$ Million) 
    Table 39. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021) (US$ Million)
    Table 40. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027) & (US$ Million)
    Table 41. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021) (US$ Million)
    Table 42. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027) & (US$ Million)
    Table 43. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021) & (US$ Million) 
    Table 44. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027) & (US$ Million) 
    Table 45. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021) (US$ Million)
    Table 48. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027) & (US$ Million)
    Table 49. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2016-2021) & (US$ Million) 
    Table 50. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2022-2027) & (US$ Million) 
    Table 51. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021) (US$ Million)
    Table 52. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027) & (US$ Million)
    Table 53. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021) (US$ Million)
    Table 54. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027) & (US$ Million)
    Table 55. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021) & (US$ Million) 
    Table 56. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027) & (US$ Million) 
    Table 57. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021) (US$ Million)
    Table 60. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027) & (US$ Million)
    Table 61. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021) & (US$ Million) 
    Table 62. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027) & (US$ Million) 
    Table 63. F. Hoffmann-La Roche Ltd Company Details
    Table 64. F. Hoffmann-La Roche Ltd Business Overview
    Table 65. F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
    Table 66. F. Hoffmann-La Roche Ltd Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
    Table 67. F. Hoffmann-La Roche Ltd Recent Development
    Table 68. Alexion Pharmaceuticals Company Details
    Table 69. Alexion Pharmaceuticals Business Overview
    Table 70. Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
    Table 71. Alexion Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
    Table 72. Alexion Pharmaceuticals Recent Development
    Table 73. RemeGen Company Details
    Table 74. RemeGen Business Overview
    Table 75. RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
    Table 76. RemeGen Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
    Table 77. RemeGen Recent Development
    Table 78. Nihon Pharmaceutical Company Details
    Table 79. Nihon Pharmaceutical Business Overview
    Table 80. Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
    Table 81. Nihon Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
    Table 82. Nihon Pharmaceutical Recent Development
    Table 83. Harbour BioMed Company Details
    Table 84. Harbour BioMed Business Overview
    Table 85. Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
    Table 86. Harbour BioMed Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
    Table 87. Harbour BioMed Recent Development
    Table 88. Lundbeck Company Details
    Table 89. Lundbeck Business Overview
    Table 90. Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
    Table 91. Lundbeck Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
    Table 92. Lundbeck Recent Development
    Table 93. Bionure Company Details
    Table 94. Bionure Business Overview
    Table 95. Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
    Table 96. Bionure Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
    Table 97. Bionure Recent Development
    Table 98. Opexa Therapeutics Company Details
    Table 99. Opexa Therapeutics Business Overview
    Table 100. Opexa Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
    Table 101. Opexa Therapeutics Recent Development
    Table 102. TG Therapeutics Company Details
    Table 103. TG Therapeutics Business Overview
    Table 104. TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
    Table 105. TG Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
    Table 106. TG Therapeutics Recent Development
    Table 107. Bio-Thera Solutions Company Details
    Table 108. Bio-Thera Solutions Business Overview
    Table 109. Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
    Table 110. Bio-Thera Solutions Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
    Table 111. Bio-Thera Solutions Recent Development
    Table 112. Boston Pharmaceuticals Company Details
    Table 113. Boston Pharmaceuticals Business Overview
    Table 114. Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
    Table 115. Boston Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
    Table 116. Boston Pharmaceuticals Recent Development
    Table 117. Cour Pharmaceutical Company Details
    Table 118. Cour Pharmaceutical Business Overview
    Table 119. Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
    Table 120. Cour Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
    Table 121. Cour Pharmaceutical Recent Development
    Table 122. Research Programs/Design for This Report
    Table 123. Key Data Information from Secondary Sources
    Table 124. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type: 2020 VS 2027
    Figure 2. Intravenous Features
    Figure 3. Oral Features
    Figure 4. Subcutaneous Features
    Figure 5. Others Features
    Figure 6. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application: 2020 VS 2027
    Figure 7. Hospital Case Studies
    Figure 8. Clinic Case Studies
    Figure 9. Others Case Studies
    Figure 10. Neuromyelitis Optica Spectrum Disorder (NMOSD) Report Years Considered
    Figure 11. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 12. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 13. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Regions: 2020 VS 2027
    Figure 14. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Regions (2022-2027)
    Figure 15. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Players in 2020
    Figure 16. Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) as of 2020
    Figure 17. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in 2020
    Figure 18. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Type (2016-2021)
    Figure 19. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Type (2022-2027)
    Figure 20. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 21. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2016-2027)
    Figure 22. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2016-2027)
    Figure 23. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2016-2027)
    Figure 24. United States Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 27. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2016-2027)
    Figure 28. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2016-2027)
    Figure 29. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2016-2027)
    Figure 30. Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. France Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. U.K. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Nordic Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2016-2027)
    Figure 38. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2016-2027)
    Figure 39. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Region (2016-2027)
    Figure 40. China Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. Southeast Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. India Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2016-2027)
    Figure 48. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2016-2027)
    Figure 49. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2016-2027)
    Figure 50. Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 53. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2016-2027)
    Figure 54. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2016-2027)
    Figure 55. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2016-2027)
    Figure 56. Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. UAE Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 59. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
    Figure 60. Alexion Pharmaceuticals Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
    Figure 61. RemeGen Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
    Figure 62. Nihon Pharmaceutical Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
    Figure 63. Harbour BioMed Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
    Figure 64. Lundbeck Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
    Figure 65. Bionure Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
    Figure 66. Opexa Therapeutics Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
    Figure 67. TG Therapeutics Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
    Figure 68. Bio-Thera Solutions Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
    Figure 69. Boston Pharmaceuticals Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
    Figure 70. Cour Pharmaceutical Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
    Figure 71. Bottom-up and Top-down Approaches for This Report
    Figure 72. Data Triangulation
    Figure 73. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
F. Hoffmann-La Roche Ltd
Alexion Pharmaceuticals
RemeGen
Nihon Pharmaceutical
Harbour BioMed
Lundbeck
Bionure
Opexa Therapeutics
TG Therapeutics
Bio-Thera Solutions
Boston Pharmaceuticals
Cour Pharmaceutical
Frequently Asked Questions
Neuromyelitis Optica Spectrum Disorder (NMOSD) report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Neuromyelitis Optica Spectrum Disorder (NMOSD) report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Neuromyelitis Optica Spectrum Disorder (NMOSD) report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

West Syndrome

Global West Syndrome Scope and Market Size
West Syndrome market is segmented by com ... Read More